Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 11/20 | 0.55 |
| ▸ | PIK3C3 | Q8NEB9 | 4/20 | 0.46 |
| ▸ | MTOR | P42345 | 4/20 | 0.40 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.40 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.40 |
| ▸ | PRF1 | P14222 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | PI4KA | P42356 | 1/20 | 0.38 |
| ▸ | PTGES2 | Q9H7Z7 | 2/20 | 0.37 |
| ▸ | TOP2A | P11388 | 1/20 | 0.36 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL729741 | 0.88 | PIK3CA (0.70) | PIK3CAPIK3C3MTORPIK3CGPIK3CD | |
| SCHEMBL3105810 | 0.87 | PIK3CA (0.59) | PIK3CAPIK3C3MTORPIK3CGPIK3CD | |
| SCHEMBL3120904 | 0.83 | PIK3CA (0.59) | PIK3CAPIK3C3MTORPIK3CGPIK3CD | |
| SCHEMBL3108020 | 0.81 | CA2 (0.46) | PTGES2TOP2A | |
| SCHEMBL3108674 | 0.81 | PIK3CB (0.45) | PIK3CAMTORPIK3CGPIK3CBPTGES2 | |
| SCHEMBL3115515 | 0.80 | PIK3CA (0.59) | PIK3CAPIK3C3MTORPIK3CGPIK3CD | |
| SCHEMBL3104715 | 0.80 | PIK3CD (0.53) | PIK3CAMTORPIK3CGPIK3CDPIK3CB | |
| SCHEMBL3115921 | 0.80 | PIK3CA (0.61) | PIK3CAPIK3C3MTORPIK3CGPIK3CD | |
| SCHEMBL3118911 | 0.80 | PIK3CA (0.61) | PIK3CAPIK3C3MTORPIK3CGPIK3CD | |
| SCHEMBL3111999 | 0.80 | PIK3CA (0.60) | PIK3CAPIK3C3MTORPIK3CGPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100179143-A1 | NAPHTHYRIDINE, DERIVATIVES AS P13 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2010-07-15 | — | — | US | disclosed |
| US-20100179143-A1 | NAPHTHYRIDINE, DERIVATIVES AS P13 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2010-07-15 | — | — | US | disclosed |
| US-20100179143-A1 | NAPHTHYRIDINE, DERIVATIVES AS P13 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2010-07-15 | — | — | US | disclosed |
| EP-2154965-A1 | NAPHTHYRIDINE, DERIVATIVES AS P13 KINASE INHIBITORS | Glaxosmithkline LLC (US) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008150827-A1 | NAPHTHYRIDINE, DERIVATIVES AS P13 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-11 | — | — | WO | disclosed |
| WO-2008150827-A1 | NAPHTHYRIDINE, DERIVATIVES AS P13 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179143-A1 | NAPHTHYRIDINE, DERIVATIVES AS P13 KINASE INHIBITORS | INPP5D, PI4KA, PTEN | PIK3CA 6/4885PIK3C3 19/4885MTOR 363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.